Head and neck cancer trial pulled before it began

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Cohort A: * Stage III or IVA-B HNC without prior RT except non-sm0kers with human papillomavirus (HPV) + nasopharynx and oropharynx. HPV+ oropharynx patients who have smoked regularly in the past 5 years are eligible. * Patients with local or regional recurrence after surgery alone are eligible, as long as the recurrent stage is III or IVA-B * Age \> or = 18 * Karnofsky performance status \> 70 * No severe active infection requiring intravenous antibiotics (oral antibiotics are allowable). * Adequate renal function (creatinine \< 1.5 mg/dl), based upon blood work performed within 1 month prior to registration. * Adequate hepatic function (alkaline phosphatase and AST/ALT \< 2 x ULN) based upon bloodwork performed within 1 month prior to registration. * Adequate bone marrow function (ANC \> 1.5; platelets \> 100K) based upon blood work performed within one month prior to registration. * Adequate cardiopulmonary function (no signs of acute coronary event and/or active CHF). * No plans for other concurrent radiation therapy, chemotherapy or biologic anti-cancer therapy. Cohort B: * Platinum ineligible patients as defined by the multidisciplinary team. * Stage III or IVA-B HNC without prior RT except nonsmokers with HPV + nasopharynx and oropharynx. HPV+ oropharynx patients who have smoked regularly in the past 5 years are eligible. * Patients with local or regional recurrence after surgery alone are eligible, as long as the recurrent stage is III or IVA-B * Age \> or = 18 * KPS \> 70 * No severe active infection requiring intravenous antibiotics (oral antibiotics are allowable). * Adequate hepatic function (alkaline phosphatase and AST/ALT \< 2 x ULN) based upon bloodwork performed within 1 month prior to registration. * Adequate bone marrow function (ANC \> 1.5; platelets \> 100K) based upon bloodwork performed within one month prior to registration. * Adequate cardiopulmonary function (no signs of acute coronary event and/or active CHF). * No plans for other concurrent radiation therapy, chemotherapy or biologic anti-cancer therapy. Exclusion Criteria: * Current, recent (within 4 weeks of enrollment in this study) or planned participation in an experimental drug study other than this one. * KPS \< 70% * Expected survival \< 6 months * Early stage head and neck cancer as defined as T1N0 or T2N0 by AJCC 7th edition * Poorly controlled blood pressure, defined as systolic bp \> 150 and/or diastolic bp \> 100 despite medication. * Unstable angina. * NY Heart Association (NYHA) Grade II or greater congestive heart failure. * History of myocardial infarction or stroke within 6 months. * Clinically significant peripheral vascular disease. * Evidence of bleeding diathesis or coagulopathy. * Presence of brain or spinal cord metastases. * Major surgical procedure(s), open biopsy or significant traumatic injury within 14 days prior to initiation of radiation therapy and/or anticipation of need for major surgical procedure during the course of the study. * Minor surgical procedures such as needle/core biopsies, dental work, PEG placement, tracheostomy within 10 days prior to initiation of radiation therapy. * Carotid artery exposure or other signs of impending carotid artery hemorrhage. * History of abdominal fistula and/or gastrointestinal abdominal abscess within 6 months prior to enrollment. * Serious, non-healing wound, ulcer, or bone fracture. * Prior irradiation that would result in radiotherapy field "overlap." * Requirement for high dose oral anticoagulation (i.e., goal INR \> 2.0). "Mini-dose" anticoagulation may be used to assist in patency of central venous lines. Subcutaneous low-molecular weight heparin is allowable. * No known allergies to any of the drug therapies being used in this protocol. * No pregnancy, lactation or inability to use medically acceptable birth control if of childbearing potential.